Enhancing risk stratification and treatment decision in multiple myeloma with SKY92 gene expression profiling in real‐world data
British Journal of Haematology · 2025
DOI: 10.1111/bjh.20050 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Noa Biran und 15 weiteren Autor:innen. Beteiligte Einrichtung: Myeloma Division, Hackensack University Medical Center, Hackensack, New Jersey, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, Gene Expression Profiling. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: SkylineDx.
Abstract (Originalsprache)
Over the years, numerous prognostic markers for multiple myeloma (MM) risk classification have been identified; however, their variability can lead to inconsistent clinical interpretations. Gene expression profiling (GEP) signatures, such as SKY92, offer a more accurate method for patient stratification. The PRospective Observational Multiple Myeloma Impact Study (NCT02911571) aimed to validate SKY92's prognostic performance using real‐world data and assess its impact on risk classification and treatment decisions compared to conventional markers. In a study of 251 newly diagnosed MM patients, physicians completed questionnaires to capture risk classification, hypothetical treatment plans and their confidence in those plans before and after unblinding SKY92 results. Poor concordance was observed between initial clinical risk assessment (iCRA) and SKY92 results (high risk: 51% iCRA vs. 28% SKY92, Cohen's κ = 0.21). SKY92 showed superior performance in identifying high‐risk patients, leading to better predictions of progression‐free survival and overall survival ( p ≤ 0.0001) than traditional risk markers. Unblinding SKY92 results led to hypothetical treatment revisions for 50% of patients ( p < 0.001) and increased physicians' confidence in treatment decisions for 40% of cases. These findings support SKY92's prognostic value in identifying high‐risk MM patients, outperforming traditional risk markers and demonstrating the potential added value of its integration into clinical practice for more personalized risk assessment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Myeloma Division, Hackensack University Medical Center, Hackensack, New Jersey, USA.
- Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
- Division of Hematology & Medical Oncology, Weill Cornell Medicine/New York Presbyterian Hospital, New York, New York, USA.
- Division of Hematology and Oncology, Columbia University Medical Center, New York, New York, USA.
- Atrium Health Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, USA.
- Lombardi Comprehensive Cancer Center, Medstar Georgetown Medical Center, Washington, District of Columbia, USA.
ORCID-Profile: Noa Biran, Binod Dhakal, Divaya Bhutani, Ajay Nooka, Barry Paul, Silvia D'Ambrosi
Förderung
- SkylineDx
Zitieren
APA
Biran, N., Dhakal, B., Niesvizky, R., Lentzsch, S., Bhutani, D., McKay, J. T., Vesole, D. H., Nooka, A., Paul, B., Hari, P. N., D'Ambrosi, S., Kuiper, R., van Vliet, M., Siegel, D., Usmani, S. Z., & van Rhee, F. (2025). Enhancing risk stratification and treatment decision in multiple myeloma with SKY92 gene expression profiling in real‐world data. British Journal of Haematology. https://doi.org/10.1111/bjh.20050
Vancouver
Biran N, Dhakal B, Niesvizky R, Lentzsch S, Bhutani D, McKay JT, et al. Enhancing risk stratification and treatment decision in multiple myeloma with SKY92 gene expression profiling in real‐world data. British Journal of Haematology. 2025. doi:10.1111/bjh.20050
BibTeX
@article{Biran2025,
author = {Biran, Noa and Dhakal, Binod and Niesvizky, Ruben and Lentzsch, Suzanne and Bhutani, Divaya and McKay, John T and Vesole, David H and Nooka, Ajay and Paul, Barry and Hari, Parameswaran N and D'Ambrosi, Silvia and Kuiper, Rowan and van Vliet, Martin and Siegel, David and Usmani, Saad Z and van Rhee, Frits},
title = {Enhancing risk stratification and treatment decision in multiple myeloma with SKY92 gene expression profiling in real‐world data},
journal = {British Journal of Haematology},
year = {2025},
doi = {10.1111/bjh.20050}
}
EUVIMED